(Q45861947)

17 December 2017

title

Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options (English)

1 reference

17 December 2017

invasive fungal infections

main subject

1 reference

10

John Perfect

1 reference

17 December 2017

Elizabeth Dodds Ashley

1

object named as

Elizabeth Dodds Ashley

1 reference

17 December 2017

author name string

Richard Drew

2

1 reference

17 December 2017

Melissa Johnson

3

1 reference

17 December 2017

Robert Danna

4

1 reference

17 December 2017

Dominika Dabrowski

5

1 reference

17 December 2017

Valery Walker

6

1 reference

17 December 2017

Manishi Prasad

7

1 reference

17 December 2017

Barbara Alexander

8

1 reference

17 December 2017

George Papadopoulos

9

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

17 December 2017

published in

Pharmacotherapy

1 reference

17 December 2017

volume

32

1 reference

17 December 2017

issue

10

1 reference

17 December 2017

page(s)

890-901

1 reference

17 December 2017

Invasive fungal infections: evolving challenges for diagnosis and therapeutics

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

The direct cost and incidence of systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Changing strategies for the management of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Burden of aspergillosis-related hospitalizations in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01124

10.1002/J.1875-9114.2012.01124

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

23033228

1 reference

17 December 2017